Duration of therapy in metastatic breast cancer: management using Herceptin®
Author:
- 1 August 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 12 (7) , 561-568
Abstract
Despite progressive developments in therapeutic interventions, including surgery, radiotherapy and chemotherapy, there has been no major improvement in the survival of women with metastatic breast cancer (MBC). Based on knowledge of tumor growth patterns, approaches addressing this issue have included increasing chemotherapy dose or dose density and extending the duration of therapy. However, only the latter approach has resulted in improved clinical benefit, although not survival; and its use is restricted by the cumulative toxicity of chemotherapeutic agents. Therefore, the best hope for improved survival lies with new classes of anticancer drug and particularly biological agents. This review focuses on the first oncogene-targeted therapy for human epidermal growth factor receptor-2 (HER2)+ MBC patients. The humanized anti-HER2 monoclonal antibody Herceptin® has proven clinical benefits in HER2+ MBC patients, most importantly improved survival, and is rapidly becoming a standard of care for these patients. In contrast to the fixed number of cycles used for chemotherapeutic agents, Herceptin is administered until disease progression, with some data suggesting that continuation beyond disease progression should be investigated. The preclinical and clinical findings on which the current recommended duration of Herceptin therapy are based are reviewed and alternative strategies are discussed.Keywords
This publication has 32 references indexed in Scilit:
- Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancerCancer Treatment Reviews, 2000
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyStem Cells, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breastEuropean Journal of Cancer, 1997
- Interrupted versus Continuous Chemotherapy in Patients with Metastatic Breast CancerNew England Journal of Medicine, 1991
- Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancerThe Lancet, 1990
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase ActivityScience, 1986